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The HA protein of the 2009 pandemic H1N1 viruses (H1N1pdm) is antigenically closely related to the HA of
classical North American swine H1N1 influenza viruses (cH1N1). Since 1998, through mutation and
reassortment of HA genes from human H3N2 and H1N1 influenza viruses, swine influenza strains are
undergoing substantial antigenic drift and shift. In this report we describe the development of a novel
monoclonal antibody (S-OIV-3B2) that shows high hemagglutination inhibition (HI) and neutralization titers
not only against H1N1pdm, but also against representatives of the α, β, and γ clusters of swine-lineage H1
influenza viruses. Mice that received a single intranasal dose of S-OIV-3B2 were protected against lethal
challenge with either H1N1pdm or cH1N1 virus. These studies highlight the potential use of S-OIV-3B2 as
effective intranasal prophylactic or therapeutic antiviral treatment for swine-lineage H1 influenza virus
infections.
© 2011 Elsevier Inc. All rights reserved.
Introduction
Influenza A viruses (IAVs) belong to the family Orthomyxoviridae
and have a segmented, negative sense single strand RNA genome
(Lamb, 1989). In addition to wild aquatic birds, which are considered
the natural hosts, IAVs have been isolated from many animal species
including humans, pigs, horses, dogs, cats, minks, marine mammals
and a wide range of domestic birds (Webster et al., 1997). The seg-
mented genome of IAVs allows for reassortment and production of
novel strains with pandemic potential. In the 20th century, humans
experienced three influenza pandemics: the Spanish flu of 1918
(H1N1), the Asian flu of 1957 (H2N2) and the Hong Kong flu of 1968
(H3N2) (Webster, 1997). These pandemic viruses carried genes
derived from avian and human IAVs. In April 2009, swine-origin
influenza H1N1 virus (H1N1pdm) caused the first influenza pandemic
of the 21st century (Donaldson et al., 2009; Jain et al., 2009; Libster
et al., 2010; Louie et al., 2010). H1N1pdm viruses are triple reassortant
viruses whose genome contains genes derived from avian (PB2 and
PA), human (PB1), North American swine (HA, NP and NS) and
Eurasian swine (NA and M) influenza lineages (Garten et al., 2009).
The HA of H1N1pdm strains is much more antigenically related to
North American swine H1 strains than to contemporary human
seasonal H1 strains. Currently, four clusters (α, β, γ, δ) of swine H1
viruses are found endemic in the North American swine population
(Ma et al., 2010; Vincent et al., 2009a, 2009b, 2010). The α, β, and γ
clusters are derived from the classical swine H1 lineage, whereas
cluster δ is derived from contemporary human H1 viruses. Phyloge-
netic analysis has shown that the HA of the H1N1pdm strains is more
closely related to the swine-origin γ cluster (Garten et al., 2009; Smith
et al., 2009). H1 viruses of the γ cluster, including H1N1pdm, showed
substantial antigenic drift compared to the prototypical classical
swine H1 viruses. Serological analysis using HI assays revealed that
sera against the classical swine H1 viruses showed either limited or no
cross-reaction to the H1N1pdm viruses (Garten et al., 2009). Sera
against current swine-lineage α, β, and γ clusters and commercial
vaccine strains in the North American swine population had limited
cross-reaction to H1N1pdm strains (Vincent et al., 2010). There is a
constant risk of two-way influenza transmission events between pigs
and humans that may lead to novel strains. Indeed, more than ten
human cases of infection with swine influenza viruses were reported
prior to the emergence of the H1N1pdm virus (Shinde et al., 2009).
Although the progenitor of the H1N1pdm virus was never isolated
in pigs prior to the emergence of the H1N1pdm virus itself, in-
fection of pigs has been documented recurrently since the pandemic
virus emerged in humans. In addition, the H1N1pdm has occasionally
transferred to other animal species such as turkeys, cats, ferrets,
cheetahs and dogs (Berhane et al., 2010; Howden et al., 2009;
Weingartl, 2010; Weingartl et al., 2010). H1N1pdm virus infection in
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swine has been reported in Canada, Argentina, Australia, Singapore,
Northern Ireland, Finland, Iceland, England, United States, Japan and
China (Berhane et al., 2010; Maines et al., 2009; Pereda et al., 2010;
Smith et al., 2009; Vijaykrishna et al., 2010).
Vaccines to novel influenza viruses take several months to produce
and its efficacy is limited in high-risk populations such as the young, the
elderly, and the immunosuppressed. Passive immunotherapy repre-
sents a plausible anti-influenza strategy. In the past, neutralizing mAbs
against influenza virus has beendevelopedand shown to be effective for
passive protection in animal models (Hanson et al., 2006; Prabhu et al.,
2009; Simmons et al., 2007; Sui et al., 2009; Throsby et al., 2008). In this
study, we developed a monoclonal antibody, S-OIV-3B2, that reacted
against the HA of H1N1pdm viruses. Interestingly, S-OIV-3B2 had high
HI and neutralization titers against swine influenza viruses of the α, β,
and γ clusters. Furthermore, protection against lethal H1N1pdm and
prototypic swineH1challengewas achieved after a single doseof S-OIV-
3B2 administered by the intranasal route either preceding or following
virus inoculation.
Results and discussion
Characterization of mAb S-OIV-3B2 against HA of H1N1pdm
Spleen cells, obtained from a mouse immunized with Ca/04 virus,
were fused to sp2/0 myeloma cells. Four monoclonal antibodies were
isolated that showed HI activity against the H1N1pdm strains. One
monoclonal antibody, mAb S-OIV-3B2 (IgG2a), showed significant HI
activity not only against different H1N1pdm strains (A/Netherlands/
602/2009, A/Mexico/4108/2009, and A/New York/18/2009), but also
against the prototypical swine H1 strain SW30 (Table 1). This result
suggested that mAb S-OIV-3B2 recognized an epitope that is conserved
between the pandemic and the classical swine strains. S-OIV-3B2
showed no HI activity against human seasonal H1 and H3 influenza
viruses and avian H5, H7 and H9 influenza viruses. We expanded the
HI profile of S-OIV-3B2 against a panel of swine H1 influenza viruses
of clusters α, β, γ, and δ (Table 1). Microneutralization assays (MN)
showed that S-OIV-3B2 could react with viruses from clusters α, β, and
γ, but showed no reaction with viruses from cluster δ, consistent with
the observation that the latter is derived from seasonal human H1
influenza strains (Table 2). Thus, S-OIV-3B2 displays a broadHI andMN
profile against swine-lineage H1 influenza strains.
Intranasal administration of mAbS-OIV-3B2 protects against lethal
challenge with H1N1pdm and classical swine H1N1 strains
To evaluate whether S-OIV-3B2 could be used as an anti-viral
agent against swine-lineage H1 viruses, prophylactic and therapeutic
treatments were implemented in the mouse model of influenza
infection. Previously, it was shown that a mAb against the HA of H5
influenza subtypes could provide protection against highly pathogenic
H5N1 viruses using a single intranasal administration dose (Ye et al.,
2010a). The sameapproachwasutilized toascertainwhether S-OIV-3B2
could protect against swine-lineage H1 strains.
S-OIV-3B2 was delivered via intranasal droplets to 6-week old
Balb/c mice at 24 or 72 h before or after challenge with 10 MLD50 of
ma-Ca/04. The S-OIV-3B2 was not purified from the ascites; therefore
treatment doses referred herein correspond to total amount of IgG in
the ascites. Pre-treatment with 12.5 mg/kg of S-OIV-3B2 at 24 or 72 h
before challenge resulted in no signs of disease or weight loss and
100% survival (Figs. 1A and B), suggesting that the S-OIV-3B2 could be
stably maintained for at least 72 h prior to challenge. In contrast,
mock-treated mice showed exacerbated signs of disease, significant
body weight loss and succumbed to the challenge by 10 dpi. These
results show that S-OIV-3B2 not only increases the chances of sur-
vival, but also prevents the disease associated with H1N1pdm. Mice
that received S-OIV-3B2 at 24 or 72 h after challenge also showed
100% survival rates (Fig. 1A). More importantly, S-OIV-3B2 adminis-
tration at 24 h after challenge resulted in neither signs of disease nor
body weight loss. When mice received S-OIV-3B2 at 72 h after chal-
lenge, less than 15% body weight loss was observed and mice started
to recover by 7 dpi (Figs. 1A and B).
To test whether S-OIV-3B2 could provide protection against other
swine-lineage H1 viruses, the antibody was delivered to 6-week old
DBA/J2mice via intranasal droplets 24 h before or after challengewith
250 TCID50 of SW30. DBA/J2 mice were used instead of Balb/c mice
because they are more susceptible to infection with influenza viruses
and, left untreated, succumbed to a 250 TCID50 dose of SW30 virus
chosen in this study. Our data showed that treatment with 12.5 mg/kg
of S-OIV-3B2 at 24 h before or after challenge resulted in 100% sur-
vival (Fig. 1D). Administration of S-OIV-3B2 before challenge resulted
in neither signs of disease nor body weight losses (Fig. 1C). Mice
treated 24 h after challenge showed slight body weight loss but
eventually recovered from challenge. These observations are in sharp
contrast with the mock-treated mice that showed exacerbated signs
of disease, significant body weight losses, and died by 6 dpi (Fig. 1).
These results highlight the potential use of S-OIV-3B2 as an intranasal
anti-viral treatment not only for H1N1pdm infections but also for
other swine-lineage H1 strains.
Table 1
HI reaction profile of S-OIV-3B2 against different influenza viruses.
Virus Subtype HI titer
A/Brisbane/59/2007 H1N1 b10
A/Puerto Rico/8/1934 H1N1 b10
A/New Caledonia/20/1999 H1N1 b10
A/Malaya/302/1954 H1N1 b10
A/Brisbane/10/2007 H3N2 b10
A/Viet Nam/1203/2004 H5N1 b10
A/chicken/Delaware/VIVA/2004 H7N2 b10
A/guinea fowl/Hong Kong/WF10/1999 H9N2 b10
A/swine/Minnesota/02053/2008(α) H1N1 20480
A/swine/Minnesota/02093/2008(α) H1N1 20480
A/swine/North Carolina/02084/2008(β) H1N1 20480
A/swine/Kentucky/02086/2008(β) H1N1 20480
A/swine/Nebraska/02013/2008(β) H1N1 10240
A/swine/Ohio/02026/2008(γ) H1N1 20480
A/swine/Missouri/02060/2008(γ) H1N1 20480
A/swine/Iowa/02096/2008(γ) H1N1 20480
A/swine/Ohio/511445/2007(γ) H1N1 20480
A/swine/North Carolina/02023/2008(γ) H1N1 20480
A/swine/Texas/01976/2008(δ) H1N2 b10
A/swine/Iowa/02039/2008(δ) H1N2 b10
A/swine/Minnesota/02011/2008(δ) H1N2 b10
A/swine/Iowa/15/1930(classical) H1N1 20480
A/swine/Tennessee/25/1977(classical) H1N1 20480
A/Netherlands/602/2009(H1N1pdm) H1N1 20480
A/California//04/2009(H1N1pdm) H1N1 20480
A/Mexico/4108/2009(H1N1pdm) H1N1 20480
Rg-NY/18HA1: 7NL/602(H1N1pdm)a H1N1 20480
a Rg-NY/18HA1:7NL/602, reverse genetic recombinant carrying the HA gene from A/
New York/18/2009 (H1N1) and the remaining 7 genes from A/Netherlands/602/2009/
H1N1.
Table 2
Neutralization titer (NT) of S-OIV-3B2 against different viruses.
Virus Subtype NT titer
A/California//04/2009 H1N1 12800
A/swine/Iowa/15/1930(classical) H1N1 6400
A/swine/Minnesota/02053/2008(α) H1N1 25600
A/swine/Nebraska/02013/2008(β) H1N1 3200
A/swine/Missouri/02060/2008(γ) H1N1 12800
A/swine/Texas/01976/2008(δ) H1N2 b100
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Protective effect of S-OIV-3B2 shows dose dependence and specificity
to H1N1pdm
To further evaluate the antiviral activity and specificity to
H1N1pdm, we performed a dose escalation study and set up a
challenge control with the PR8 virus, to which S-OIV-3B2 does not
cross-react. Doses of 12.5 and 6.25 mg/kg administered at 24 h before
challenge resulted in 100% survival (n=5/group) and no clinical
signs. In the group treated with the lowest dose (1.25 mg/kg, n=5),
one mouse showed rapid body weight loss and died by 8 dpi, whereas
the rest of the mice survived with no clinical signs (Fig. 2). This study
shows a dose-dependent effect of S-OIV-3B2 against lethal H1N1pdm
challenge in mice. It also shows the high antiviral activity of the mAb
because administration of a single dose at just 1.25 mg/kg resulted in
80% protection. Specificity of S-OIV-3B2was achieved by showing lack
of protection against the PR8 strain even at the 12.5 mg/kg dose
(Fig. 2). S-OIV-3B2-treated mice challenged with 10 MLD50 of PR8,
succumbed to the infection by 6 dpi.
S-OIV-3B2 significantly decreases virus replication in mouse lungs
To determine whether treatment with S-OIV-3B2 resulted in re-
duced virus replication, 6-week old Balb/c mice inoculated with
12.5 mg/kg of S-OIV-3B2 at 24 h before or after challenge with 10
MLD50 of ma-Ca/04 were sacrificed at 3 dpi, lungs collected and virus
titers in lung homogenates determined. Virus titers in the lungs were
negligible in mice that received S-OIV-3B2 either before or after
challenge, indicating complete block of virus replication. Mock-treated
mice showed virus lung titers in the order of 106 TCID50 (Fig. 3). These
results strongly support the data described in Figs. 1 and 2, and suggest
that the mechanism of protective action of S-OIV-3B2 in vivo is by
binding and neutralizing the virus.
In summary, in this study we developed a monoclonal antibody –
S-OIV-3B2 – against the HA of H1N1pdm. Our results showed that
S-OIV-3B2 had high HI and neutralization titers, not only against
multipleH1N1pdmstrains, but also against classical swine and other H1
strains that belong to clusters α, β, and γ. To our knowledge, this is the
Fig. 1. Treatment effect of S-OIV-3B2 against lethal challenge of swine-lineage H1. A, B) 6-week old mice (n=5/group) were treated with 12.5 mg/kg doses of S-OIV-3B2 via the
intranasal route at 24 h and 72 h before (bc) or after challenge (ac) with 10 MLD50 of ma-Ca/04; C, D) 6-week old mice (n=5/group) were treated with 12.5 mg/kg doses of S-OIV-
3B2 via the intranasal route at 24 h before or after challenge with 250 TCID50 of SW30. Mock-treatedmice received 14 mg/kg doses of control IgGmAb (2B9) at 24 h before challenge.
A, C) Percent body weight change; B, D) percent survival.
Fig. 2. Protective effect of S-OIV-3B2 shows dose dependence and H1N1pdm antigenic specificity. 6-week old mice (n=5/group) were treated with 12.5 mg/kg, 6.25 mg/kg and
1.25 mg/kg doses of S-OIV-3B2 via the intranasal route at 24 h before challenge with 10 MLD50 of ma-Ca/04 or PR8. A) Percent body weight change; B) percent survival.
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first report demonstrating a monoclonal antibody with broad cross-
reaction against multiple swine H1 influenza lineages. In contrast,
another mAb S-OIV-5H7 developed in our laboratory showed only
reactionwithH1N1pdm strains, not against other swine H1 strains (not
shown). More recently, Wrammert et al. (2011) generated several
monoclonal antibodies against H1N1pdm but their antiviral activity or
reaction profile against other swine H1 strains was not provided.
Using S-OIV-3B2 in vitro in tissue culture cells or embryonated
chicken eggs, we could not obtain H1N1pdm escape mutant virus
(data not shown); however, it may be that escape mutants would
readily emerge if tested under in vivo conditions. Nevertheless,
despite the significant antigenic drift that has occurred between the
classical swine H1 strains and current endemic swine-lineage H1 in
the North American swine population, it is tempting to speculate that
S-OIV-3B2 targets a highly conserved epitope. The high neutralization
titer of S-OIV-3B2 against swine-lineage H1 further confirms the HI
profile and also indicates its potential immune passive therapy against
swine-lineage H1 influenza viruses.
Since development of vaccines against a pandemic strain usually
takes several months and strains resistant to available antiviral drugs
can readily occur (de Jong et al., 2005; Le et al., 2005; Reece, 2007),
passive antibody immune therapy represents an attractive alternative
antiviral strategy. It is the strategy of choice for the prevention and
treatment of respiratory syncytial virus (RSV) infections in high-risk
infants where a large dose of a “humanized” IgG mAb is injected
intravenously or intramuscularly (Hu and Robinson, 2010). Recently,
monoclonal antibodies against highly pathogenic H5N1 influenza virus
have been reported as potential antiviral treatment of H5N1 infection in
the mouse model (Prabhu et al., 2009; Simmons et al., 2007; Sui et al.,
2009; Throsby et al., 2008). These studies showed the administration of
passive antibodies via the intraperitoneal, intramuscular or intravenous
routes. More recently, we developed amonoclonal antibody that, when
administered as a single dose intranasally, provided protection against
highly pathogenic H5N1 (Ye et al., 2010a). Here intranasal administra-
tion was again used to show that S-OIV-3B2 could provide protection
against lethal challenge with classical swine H1N1 and H1N1pdm
influenza strains. It should be noted that S-OIV-3B2 maintained virus
neutralization activity even when given 72 h prior to challenge. This
result further confirms our previous finding that the neutralization
activity of a monoclonal antibody is retained at least for 3 days in the
mouse respiratory tract (Ye et al., 2010a). S-OIV-3B2 was also effective
when given at 72 h post-challenge and significantly reduced the
morbidity in Balb/cmice. Previous studies showed a humanmonoclonal
antibody (A06) derived from a survivor of highly pathogenic H5N1
infection that could also protect mice from H1N1pdm infection if the
antibody was administered intraperitoneally (Kashyap et al., 2010).
However, these studies did not determine whether A06 was effective if
administered 48 or 72 h prior to infection. Similarly, A06 treatment
resulted in 100% and 50% survival when given at 24 h or 72 h post
challenge, respectively. It should also be noted that the challenge dose
(25 MLD50) used by Kashyap et al. (2010) is slightly higher than in our
study (10 MLD50) in Balb/c mice. Considering the limited efficacy of
current antiviral drugs when given beyond the 48 h window after
infection, antibody-mediated therapy should be considered a plausible
strategy against influenza (Cram et al., 2001; Gillissen and Hoffken,
2002). Future studies are needed to determine whether S-OIV-3B2 can
be “humanized” while maintaining its neutralizing antiviral activity.
Materials and methods
Cells and virus
sp2/0 myeloma cells (ATCC, Manassas, VA, USA) were cultured in
modified Eagle's medium (MEM) (Sigma-Aldrich, St. Louis, MO, USA)
supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich,
St. Louis, MO, USA). Madin–Darby canine kidney (MDCK) cells (ATCC,
Manassas, VA, USA) were maintained in MEM containing 5% FBS. A/
California/04/2009 (H1N1) virus (Ca/04) was kindly provided by the
Centers for Disease Control and Prevention (CDC), Atlanta, Georgia,
USA. A/swine/Iowa/15/1930(H1N1) virus (Sw30) was obtained from
the ATCC (Manassas, VA, USA). Mouse-adapted A/California/04/2009
(H1N1) virus (ma-Ca/04) was developed in our laboratory (Ye et al.,
2010b). Viruses were propagated in MDCK cells and stored at−70 °C
until use. All viruses were titrated by the Reed–Muench method to
determine the TCID50 and MLD50 (Reed and Muench, 1938).
Immunization
Eight-week old female Balb/c mice were immunized by intraper-
itoneal injection with Ca/04. Doses consisted of 200 μl of supernatant
containing 2×105 TCID50 of virus. Boost immunizations were given at
10, 20 and 30 days post-vaccination. Animal studies using the Ca/04
virus were conducted under BSL-3 conditions and performed accord-
ing to protocols approved by the Institutional Animal Care and Use
Committee of the University of Maryland-College Park.
Production of mAbs
Mouse spleen cells collected at 4 days after the 3rd immunization
boost with Ca/04 were fused to the sp2/0 myeloma cells as previously
described (Yang et al., 2008). After selection of the hybridomas in
hypoxanthine aminopterin thymidine media (HAT) (Invitrogen,
Carlsbad, CA, USA), antibody producing cells were screened by the
hemagglutination inhibition (HI) method (Webster et al., 2005) and
sub-cloned by limiting dilution. Positive clones were checked for
isotype by using Iso-Gold™ Rapid Mouse-Monoclonal Isotyping Test
Kit (BioAssay Works, Ijamsville, MD, USA) as described in the
manufacturer's protocol. The mAb's ascites were generated as
previously described (Yang et al., 2008). Total protein concentration in
the ascites was quantified by two independent methods: bicinchoninic
acid protein assay kit (Pierce, Rockford, IL, USA) and protein absorbance
at280 nmusing theNanoDropND-1000photometer (ThermoScientific,
Wilmington, DE, USA). Total IgG concentration in the ascites was
quantified using the mouse IgG ELISA kit (Immunology Consultants
Laboratory, Inc., Newberg, OR, USA).
Neutralization assays
For microneutralization (MN) assays, serially diluted mAbs were
first incubated with 100 TCID50 of viruses for 1 h at 37 °C (Table 2). The
virus–mAb mixture was then absorbed to MDCK cells for 1 h at 37 °C.
Infected cells were washed twice with phosphate buffered saline (PBS)
and replenished with Opti-MEM (Gibco, Grand Island, NY, USA). The
Fig. 3. S-OIV-3B2 inhibits lung virus replication in challenged mice. Mice (n=3/group)
were treated with 12.5 mg/kg of S-OIV-3B2 at 24 h before (bc) or after challenge (ac)
with 10 MLD50 of ma-Ca/04. The mock-treated mice received 14 mg/kg doses of control
IgG mAb (2B9) at 24 h before challenge. At day 3 post-challenge, lungs were
homogenized and viruses in homogenates were titrated in MDCK cells. BLD, below
the limit detection.
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infected cell supernatants were harvested at 4 days post-infection (dpi)
and were analyzed by HA assay (Webster et al., 2005).
Protection studies in mice
The ascites were filtered using a 0.22 μm filter and then inactivated
at 56 °C for 30 min. Six-week old mice (n=5/group) were treated via
the intranasal routewitha singledoseof 50 μl PBSpermouse (divided in
equal parts in eachnostril) containing12.5 mg/kgof total IgG containing
the S-OIV-3B2mAb (as indicated above). The treatmentwas performed
at different time points before or after challenge as indicated in the
Results and discussion section.Mock-treatedmice received 14 mg/kg of
total IgG containing the control 2B9 mAb (against the NP viral protein,
prepared in our laboratory). Two different strains were used for chal-
lenge, ma-Ca/04 and SW30, at doses of 10 MLD50 of ma-Ca/04 and 250
TCID50 of SW30, respectively. Dose dependence evaluation was per-
formed with mice receiving 12.5 mg/kg, 6.25 mg/kg and 1.25 mg/kg
of total IgG containing the S-OIV-3B2 mAb at 24 h before challenge.
Specificity to H1N1pdm antiviral activity was evaluated with mice
treated with the high dose of S-OIV-3B2 mAb (12.5 mg/kg total IgG)
administered24 hbefore challengewith10MLD50 of influenzaA/Puerto
Rico/8/34 (H1N1) (PR8), which does not react to S-OIV-3B2mAb. Body
weight changes, morbidity and mortality were monitored daily. Mice
showing body weight losses ≥25% of pre-infection values were
euthanized for ethical reasons. Challenge studies were conducted
under BSL-3 conditions approved by USDA and performed according
to protocols approved by the Institutional Animal Care and Use
Committee of the University of Maryland, College Park.
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